LB Pharmaceuticals announced a private placement agreement to sell 3,577,560 common shares and pre-funded warrants for up to 715,513 additional shares at $34.94 per share. The company expects to raise approximately $150 million in gross proceeds before expenses. The financing includes participation from new and existing institutional investors, including Adage Capital Partners, BB Biotech, and funds managed by Farallon Capital Management. Leerink Partners and Piper Sandler served as placement agents. LB Pharmaceuticals intends to use the net proceeds to fund pipeline expansion of LB-102 into new indications, including negative symptoms of schizophrenia and Alzheimer's disease agitation and psychosis. The company will also use funds for working capital and general corporate purposes. The transaction is expected to close on or about 30 July 2026, subject to customary closing conditions.

Shapoorji Pallonji Group has secured Rs 21,500 crore in its first funding tranche through rupee and dollar-denominated debt, with the issue fully subscribed by domestic and global institutional investors. The rupee bonds, with three-year tenure, were priced to yield about 18.95%, whilst the dollar tranche carries a yield of around 14.5%. The first tranche comprises Rs 15,200 crore in rupee-denominated issuance and approximately $650 million from offshore dollar investors. Investors include Deutsche Bank, BlackRock, Davidson Kempner Capital Management, Varde Partners, Ares Management, and Goldman Sachs Asset Management, amongst others. The fundraising, backed by the group's 18.37% stake in unlisted Tata Sons, aims to replace higher-cost debt. Funding is scheduled to complete on 20 July.